DailyPharm: Hanlim Pharmaceutical drives open innovation… expanding ophtalmique partners
Scale of ophtalmique drug transfert de technologie with RudaCure expands to over KRW 20 billion
Focused investissement in macular degeneration biosimilars… partenariats with Altos Bio and others
Stable cash generation capacity connects to external investissement… second-generation owner also supports
[DailyPharm = Reporter Lee Seok-joon] Hanlim Pharmaceutical is accelerating its open innovation drive. En particulier, it has partnered with multiple companies to expand its core ophtalmique business. The scale of transferts de technologie with RudaCure has exceeded KRW 20 billion.
The expansion of the open innovation business is underpinned by Hanlim Pharmaceutical's strong operating cash generation capability. L'entreprise has been achieving an operating profit margin of around 15% for several years. The second-generation owner is also providing support.
Hanlim Pharmaceutical récemment completed a transfert de technologie of RudaCure's ulcère cornéen and traitement des lésions cornéennes candidate (RCI001U). Hanlim Pharmaceutical will hold national production and sales rights for RCI001U technology, while RudaCure will receive étape clé payments notamment approbation d'essai cliniques. The deal is worth KRW 7 billion (notamment an upfront payment of KRW 1 billion).
